within Pharmacolibrary.Drugs.ATC.H;

model H01CC54
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.12,
    Cl             = 27.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,
    adminCount     = 1,
    Vd             = 0.4,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Relugolix, estradiol, and norethisterone is a fixed-dose combination oral medication used for the management of symptoms associated with uterine fibroids, such as heavy menstrual bleeding, in premenopausal women. Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol is a natural estrogen, and norethisterone is a synthetic progestin. This combination is approved for use in several regions and is commonly marketed under the name Myfembree.</p><h4>Pharmacokinetics</h4><p>Estimate for healthy premenopausal adult females receiving standard oral therapeutic dose as per approved label.</p><h4>References</h4><ol><li><p>Brimhall, DB, et al., &amp; Ufer, M (2025). Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women. <i>Pharmacology research &amp; perspectives</i> 13(1) e70067â€“None. DOI:<a href=&quot;https://doi.org/10.1002/prp2.70067&quot;>10.1002/prp2.70067</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39887952/&quot;>https://pubmed.ncbi.nlm.nih.gov/39887952</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end H01CC54;
